Duchenne muscular dystrophy (DMD) is an X-linked recessive disorder affecting approximately 1 of 3,500 newborn human males in which absence of the protein dystrophin causes progressive degeneration of skeletal and cardiac muscle. Currently no treatment halts or reverses progression of DMD. Although cellular and gene therapies are promising, key questions must first be addressed in relevant animal models. Spontaneous forms of X-linked muscular dystrophy due to dystrophin deficiency have been identified in mice, multiple dog breeds, and cats. Unlike the dystrophin-deficient mdx mouse, which remains relatively normal clinically, affected dogs develop progressive, fatal disease strikingly similar to the human condition. Accordingly, studies in the canine dystrophin deficient models, such as golden retriever muscular dystrophy (GRMD), are more likely than those in mdx mice to predict pathogenesis and outcome of treatment in DMD. Using FDA recommendations as a guiding principle, we have formulated a research initiative titled the National Center for Canine Models of Duchenne Muscular Dystrophy (NCDMD). The overarching goal of the NCDMD is to develop and sustain dog models of DMD and expand country-wide collaborations with investigators pioneering translational research focused on the treatment of DMD. UNC is uniquely positioned to carry out this initiative having successfully developed a similar structure for the UNC hemophilic canine model. The emerging need for access to the GRMD and other DMD canine models is becoming imminent. Five therapeutic approaches detailed later in this summary are representative of the various approaches that have shown promise in the mdx mouse and are now poised for further studies in canine models before entering clinical studies. Without the proposed NCDMD, it will be virtually impossible to meet the increasing demand to utilize GRMD and other canine models of DMD in critical preclinical studies required for human clinical trials. The NCDMD will also provide high quality facilities and services in compliance with GLP standards to support pre-IND applications.

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Resource-Related Research Projects--Cooperative Agreements (U24)
Project #
5U24NS059696-03
Application #
7925810
Study Section
National Institute of Neurological Disorders and Stroke Initial Review Group (NSD)
Program Officer
Porter, John D
Project Start
2008-05-01
Project End
2012-04-30
Budget Start
2011-05-01
Budget End
2012-04-30
Support Year
3
Fiscal Year
2011
Total Cost
$1
Indirect Cost
Name
University of North Carolina Chapel Hill
Department
Pathology
Type
Schools of Medicine
DUNS #
608195277
City
Chapel Hill
State
NC
Country
United States
Zip Code
27599
Kornegay, Joe N; Bogan, Daniel J; Bogan, Janet R et al. (2016) Dystrophin-deficient dogs with reduced myostatin have unequal muscle growth and greater joint contractures. Skelet Muscle 6:14
Brinkmeyer-Langford, Candice; Balog-Alvarez, Cynthia; Cai, James J et al. (2016) Genome-wide association study to identify potential genetic modifiers in a canine model for Duchenne muscular dystrophy. BMC Genomics 17:665
Wang, Jiahui; Vachet, Clement; Rumple, Ashley et al. (2014) Multi-atlas segmentation of subcortical brain structures via the AutoSeg software pipeline. Front Neuroinform 8:7
Fan, Zheng; Wang, Jiahui; Ahn, Mihye et al. (2014) Characteristics of magnetic resonance imaging biomarkers in a natural history study of golden retriever muscular dystrophy. Neuromuscul Disord 24:178-91
DeVanna, Justin C; Kornegay, Joe N; Bogan, Daniel J et al. (2014) Respiratory dysfunction in unsedated dogs with golden retriever muscular dystrophy. Neuromuscul Disord 24:63-73
Kornegay, Joe N; Spurney, Christopher F; Nghiem, Peter P et al. (2014) Pharmacologic management of Duchenne muscular dystrophy: target identification and preclinical trials. ILAR J 55:119-49
Martin, Paul T; Golden, Bethannie; Okerblom, Jonathan et al. (2014) A comparative study of N-glycolylneuraminic acid (Neu5Gc) and cytotoxic T cell (CT) carbohydrate expression in normal and dystrophin-deficient dog and human skeletal muscle. PLoS One 9:e88226
Cotten, Steven W; Kornegay, Joe N; Bogan, Daniel J et al. (2013) Genetic myostatin decrease in the golden retriever muscular dystrophy model does not significantly affect the ubiquitin proteasome system despite enhancing the severity of disease. Am J Transl Res 6:43-53
Wang, Jiahui; Fan, Zheng; Vandenborne, Krista et al. (2013) A computerized MRI biomarker quantification scheme for a canine model of Duchenne muscular dystrophy. Int J Comput Assist Radiol Surg 8:763-74
Nghiem, Peter P; Hoffman, Eric P; Mittal, Priya et al. (2013) Sparing of the dystrophin-deficient cranial sartorius muscle is associated with classical and novel hypertrophy pathways in GRMD dogs. Am J Pathol 183:1411-24

Showing the most recent 10 out of 15 publications